BB 1709
Alternative Names: BB-1709Latest Information Update: 11 Mar 2024
At a glance
- Originator Bliss Biopharmaceutical
- Class Antineoplastics; Drug conjugates; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Oct 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT06241898)